Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Advanced Pancreatic Cancer Trial - NU 18I01
View:
Post by Quentin30 on Nov 22, 2022 6:52pm

Advanced Pancreatic Cancer Trial - NU 18I01

Another poster recently mentioned more data from the other Pancreatic Cancer trial in combination with Keytruda.

Well, this is from ClinicalTrials.Gov.

Terminated 
(The total accrual goal of 34 patients was not met. Stage 1 of the study did not meet the interim analysis criteria to move onto Stage 2 of the Simon 2 stage design.)

So, I find it somewhat peculiar that ONCY still have this trial listed in their pipeline, when the trial was terminated and went no further. It failed to meet the criteria to move into Phase II. Safe and well tolerated, but nothing else.

Still think this company is worth 8 billion..?
Comment by Noteable on Nov 22, 2022 7:45pm
ONCY decided to go with the Goblet-1 pancreatic cancer study instead since it was a multi-centered study with a significantly reputable German clinical reserach group known as AOI. The pancreatic study included the biomarker work and was successfully reported on at the KOL meeting held on November 14, 2022.  The following pancreatic cancer results were achieved: November 10, 2022 One ...more  
Comment by Quentin30 on Nov 22, 2022 7:54pm
When in doubt... just post something else...  As for the Goblet-1 data... well the market thought a lot of that... we're back down to where we were prior to the presentation... and thus the impact was.. a big fat NIL. If you are so convinced ONCY will be bought out soon for megbucks, how bout you make me an offer of 3 bucks on all my ONCY stock. :-)
Comment by Noteable on Nov 22, 2022 7:59pm
Yep ....the Goblet-1 pancreatic study delivered the goods. Data suggest pelareorep synergizes with PD-(L)1 inhibitors and standard-of-care chemotherapy in advanced/metastatic pancreatic ductal adenocarcinoma Oncolytics plans to present pancreatic cancer data to regulators to determine the most expeditious path to approval
Comment by Buckhenry on Nov 22, 2022 8:06pm
sounds like u have 3 choices Quentin... sell...hold...or seek therapy for your bitterness. 
Comment by Hcallahan44 on Nov 22, 2022 8:45pm
lol quentin....yea canada how about 3 a share for my 62 k....tell you what i will give you the few understand discount and give them all to you for 2.50.....
Comment by CarbonWarrior on Nov 22, 2022 10:53pm
Wow the bitterness here is intense. Hope is gone. Now the time to buy buy buy like crazy. Look, drowning in your sorrows isn't going to make SP go up. The bottom line is that this company had a very advance product for its time (a virus). They did not know how to harness it. Took forever and now they have 3 or even 4 shot at it -Pancreatic -Breast cancer -Skin (yes this one might pop back)  ...more  
Comment by Lesalpes29 on Nov 23, 2022 6:29am
Not going to buy all your shares for 3$, I’m not rich enough! But Quinntinnn why don’t you sell your shares on open market if you are so sure it’s going lower and lower and lower...? 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities